Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/5/533 |
| _version_ | 1827667424147668992 |
|---|---|
| author | Miriam Alonso-García Amparo Sánchez-Gastaldo Miguel A. Muñoz-Fuentes Sonia Molina-Pinelo Laura Boyero Johana Cristina Benedetti Reyes Bernabé-Caro |
| author_facet | Miriam Alonso-García Amparo Sánchez-Gastaldo Miguel A. Muñoz-Fuentes Sonia Molina-Pinelo Laura Boyero Johana Cristina Benedetti Reyes Bernabé-Caro |
| author_sort | Miriam Alonso-García |
| collection | DOAJ |
| description | Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (<i>n</i> = 89) or PD-L1 (atezolizumab) (<i>n</i> = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (<i>p</i> = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, <i>p</i> = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, <i>p</i> = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (<i>p</i> < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab. |
| first_indexed | 2024-03-10T03:10:29Z |
| format | Article |
| id | doaj.art-6c4ab7e0320e4541932945c15fccdbcf |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T03:10:29Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-6c4ab7e0320e4541932945c15fccdbcf2023-11-23T12:34:05ZengMDPI AGPharmaceuticals1424-82472022-04-0115553310.3390/ph15050533Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung CancerMiriam Alonso-García0Amparo Sánchez-Gastaldo1Miguel A. Muñoz-Fuentes2Sonia Molina-Pinelo3Laura Boyero4Johana Cristina Benedetti5Reyes Bernabé-Caro6Medical Oncology Department, Hospital Universitario Virgen del Rocío, 41013 Seville, SpainMedical Oncology Department, Hospital Universitario Virgen del Rocío, 41013 Seville, SpainInstitute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, 41013 Seville, SpainInstitute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, 41013 Seville, SpainInstitute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, 41013 Seville, SpainMedical Oncology Department, Hospital Universitario Virgen del Rocío, 41013 Seville, SpainMedical Oncology Department, Hospital Universitario Virgen del Rocío, 41013 Seville, SpainNivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (<i>n</i> = 89) or PD-L1 (atezolizumab) (<i>n</i> = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (<i>p</i> = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55–1.17, <i>p</i> = 0.260; OS HR: 0.79, 95% CI: 0.52–1.21, <i>p</i> = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (<i>p</i> < 0.001). Atezolizumab and nivolumab did not show statistically significant differences in survival outcomes in patients with NSCLC, even when stratified by histological subtype (squamous versus nonsquamous). However, the safety analysis suggested a more favourable toxicity profile for atezolizumab.https://www.mdpi.com/1424-8247/15/5/533atezolizumabimmune checkpoint inhibitors (ICIs)immunotherapynivolumabnon-small cell lung cancer (NSCLC)real-world data |
| spellingShingle | Miriam Alonso-García Amparo Sánchez-Gastaldo Miguel A. Muñoz-Fuentes Sonia Molina-Pinelo Laura Boyero Johana Cristina Benedetti Reyes Bernabé-Caro Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer Pharmaceuticals atezolizumab immune checkpoint inhibitors (ICIs) immunotherapy nivolumab non-small cell lung cancer (NSCLC) real-world data |
| title | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| title_full | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| title_fullStr | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| title_full_unstemmed | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| title_short | Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer |
| title_sort | real world analysis of nivolumab and atezolizumab efficacy in previously treated patients with advanced non small cell lung cancer |
| topic | atezolizumab immune checkpoint inhibitors (ICIs) immunotherapy nivolumab non-small cell lung cancer (NSCLC) real-world data |
| url | https://www.mdpi.com/1424-8247/15/5/533 |
| work_keys_str_mv | AT miriamalonsogarcia realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT amparosanchezgastaldo realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT miguelamunozfuentes realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT soniamolinapinelo realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT lauraboyero realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT johanacristinabenedetti realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer AT reyesbernabecaro realworldanalysisofnivolumabandatezolizumabefficacyinpreviouslytreatedpatientswithadvancednonsmallcelllungcancer |